Dravet syndrome is a rare epileptic disorder affecting infants. The patient has seizures which are triggered by hot temperatures or fevers. It is also known as severe myoclonic epilepsy of infancy (SMEI). According to the National Center for Advancing Sciences, nearly 15-25% of the cases of the disorder have a family history of febrile seizures or epilepsy. The global Dravet syndrome market report by Market Research Future (MRFR) has been compiled by a blend of primary and secondary research.

Market Overview

The global Dravet syndrome market share is expected to magnify its valuation at 8.5% CAGR during the forecast period. The increase noticed in the health expenditure for research and development (RD) and development of new therapies are primary factors expected to drive the market growth. Other major drivers include reimbursement policies offering coverage of rare diseases, improvement in regulatory framework, and unmet medical needs of patients.

Adverse effects of the drugs, low awareness of the disease, and low planning of healthcare in low and mid income countries are some of the restraints which can impede market growth.

Competition Outlook

Ovid Therapeutics, OPKO Health Inc., Zogenix, Inc, Biocodex, Biscayne Neurotherapeutics, Takeda Pharmaceutical Company Limited, Sage Therapeutics, Xenon Pharmaceuticals, INSYS THERAPEUTICS, INC., Epygenix Therapeutics, Inc., Thermo Fisher Life Technologies, PTC Therapeutics, GW Pharmaceuticals, plc, and Cyberonics, Inc. are the biggest players in the global Dravet syndrome market.

Segmentation

The global Dravet syndrome market is segmented on the basis of the type of seizures, diagnosis, treatment management, and end-user.

On the basis of the type of seizures, it is classified as myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic clonic seizures, photosensitive seizures, and others.

On the basis of the diagnosis, it is segmented as magnetic resonance imaging (MRI), electroencephalography (EEG), SCN1A testing, and others.

On the basis of the treatment management, the market is segmented into seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others. The seizure medications segment is further classified into clobazam, stiripentol, sodium valproate, and others.

On the basis of the end-user, the global Dravet syndrome market is segmented into pharmaceutical companies, hospitals, diagnostic laboratories, academic and research institutes, and others.

Regional Analysis

The Americas, Europe, the Middle East Africa (MEA), and Asia Pacific (APAC) are the major segments according to region.

The Americas are presumed to dominate the global market till 2023 due to the increased healthcare budget by governments in the region for the welfare of their patients. Presence of large number of players and continuous development of drugs due to ongoing clinical trials are other drivers of the region.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America